Nanobiotix Transfers Nanoray-312 Sponsorship to Johnson & Johnson-March 2024-www.financetom.com

Nanobiotix Transfers Nanoray-312 Sponsorship to Johnson & Johnson

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Nanobiotix Transfers Nanoray-312 Sponsorship to Johnson & Johnson

Oct 24, 2025 1:31 AM

04:11 AM EDT, 10/24/2025 (MT Newswires) -- Nanobiotix ( NBTX ) said Friday it has transferred Nanoray-312 sponsorship to Johnson & Johnson ( JNJ ) , including the transfer of operational control of the phase 3 head and neck cancer study.

The company expects that Nanoray-312, which started in Q3 2024, interim data will be analyzed and reported in H1 2027, Nanobiotix ( NBTX ) said.

Johnson & Johnson ( JNJ ) will provide future updates regarding Nanoray-312 and other JNJ-1900-related sponsored trials, while Nanobiotix ( NBTX ) will continue to offer JNJ-1900 clinical development updates, according to the company.

JNJ-1900 oncology product is being evaluated throughout multiple solid tumor indications as a single agent or combination therapy.

Previous page： Netskope Seeks to Raise Up to $812.6 million in IPO Next page： Dianthus Therapeutics Says Claseprubart Showed Meaningful Improvements in Myasthenia Gravis Patients

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Netskope Seeks to Raise Up to $812.6 million in IPO

Sep 8, 2025

08:26 AM EDT, 09/08/2025 (MT Newswires) -- Netskope expects to raise between $717 million and $812.6 million in its initial public offering, according to a Monday filing with the US Securities and Exchange Commission. The cloud-security provider said it will offer 47.8 million class A common shares, expected to be priced between $15 and $17 per share. Underwriters have been...

Dianthus Therapeutics Says Claseprubart Showed Meaningful Improvements in Myasthenia Gravis Patients

Sep 8, 2025

08:29 AM EDT, 09/08/2025 (MT Newswires) -- Dianthus Therapeutics ( DNTH ) said Monday claseprubart demonstrated statistically significant and clinically meaningful improvements in a phase 2 study of adults with acetylcholine receptor antibody positive generalized myasthenia gravis. The therapy improved daily living and muscle strength scores as early as the first week and maintained benefits through week 13, the company...

Oncolytics Says Pelareorep Drug Shows 'Strong Efficacy, Translational Data' in Metastatic Colorectal Cancer

Sep 8, 2025

08:28 AM EDT, 09/08/2025 (MT Newswires) -- Oncolytics Biotech ( ONCY ) said Monday that data from three metastatic colorectal cancer, or mCRC studies for its immunotherapy pelareorep showed consistent efficacy signals, immune activation, and survival outcomes that exceeded benchmarks in multiple treatment settings. The REO 022 trial, which evaluates pelareorep in combination with Folfiri and bevacizumab in platinum refractory...

Marqeta Announces Appointment of Mike Milotich as CEO

Sep 8, 2025

08:28 AM EDT, 09/08/2025 (MT Newswires) -- Marqeta ( MQ ) said Monday it has appointed Mike Milotich as chief executive officer, effective today. The company said Milotich has served as interim CEO since February, in addition to his role of chief financial officer. He will continue to serve as CFO until a successor has been identified, the company said....